Abstract. The association between long non-coding RNA zinc finger antisense 1 (ZFAS1) and acute myeloid leukemia (AML) has not yet been investigated. The present study aimed to assess the potential role of ZFAS1 in AML cell proliferation and apoptosis. The expression of ZFAS1 mRNA in various AML cell lines (HL‑60, KG‑1, ML‑1 and SKNO‑1) was measured by reverse transcription‑quantitative polymerase chain reaction. The results showed that ZFAS1 expression was increased in all four human AML cell lines compared with the control cell lines (T lymphocytic leukemia or Burkitt's lymphoma). Transfection with small interfering RNA into human AML cells established ZFAS1 knockdown. A cell‑counting kit‑8 (CCK‑8) assay was used to investigate the effect of ZFAS1 on AML cell proliferation and the effect of ZFAS1 on the cell cycle and cell apoptosis was assessed using flow cytometry. Notably, the CCK‑8 assay demonstrated that ZFAS1 knockdown inhibited cell proliferation in HL‑60 and SKNO‑1 cell lines and flow cytometry analysis indicated that ZFAS1 knockdown induced AML cell cycle G1 phase arrest and triggered cell apoptosis. Therefore, the present study indicated that ZFAS1 promoted the proliferation and inhibited the apoptosis of AML cells.

Introduction

Acute myeloid leukemia (AML) is a highly heterogeneous form of hematopoietic malignancies; aberrantly differentiated myeloid cells grow rapidly in the bone marrow and other tissues, thereby inhibiting normal hematopoiesis and immune function, and infiltrating other organs (1,2). AML incidence increases with age and older patients typically exhibit a lower long‑term overall survival rate (3). The formation of AML has been associated with multiple factors, including radiation, chemical degradation, viral infection and multiple susceptible genes (4). Although the overall prognosis of AML has improved markedly in recent years, the pathophysiological mechanism of AML development remains unknown. To increase the survival rate of patients with AML, it is of paramount importance to improve comprehension of its molecular pathogenesis and identify prognostic markers of AML.

Long non-coding RNAs (lncRNAs) are transcripts >200 nucleotides long that are not translated into proteins (5). Previous studies have indicated that various lncRNAs may be associated with specific biological processes, including chromatin modification, epigenetic regulation, the cell cycle, cell apoptosis and differentiation (6-8). LncRNAs are commonly dysregulated in the pathological processes of cancer, and may therefore serve as prognostic markers (9,10).

It has been reported that zinc finger antisense 1 (ZFAS1), a newly identified IncRNA that maps to chromosome 20q13.13, is highly expressed in the mammary gland and downregulated in breast tumors (11). Li et al (12) and Thorenoor et al (13) reported that ZFAS1 functions as an oncogene in hepatocellular and colorectal carcinoma progression, and is associated with cancer cell cycle progression, metastasis and poor prognosis. Previous studies have also demonstrated that a variety of IncRNAs are closely associated with hematological malignancies (14-16). However, the role of ZFAS1 in AML remains unknown; therefore, the present study investigated its effects in various AML cell lines. Cell proliferation and apoptosis, which serve important roles in AML cell development and progression, were the primary mechanisms assessed to determine the effects of ZFAS1 on AML in the present study.

Materials and methods

Cell lines. Four human AML cell lines (HL‑60, KG‑1, ML‑1 and SKNO‑1), a T lymphocytic leukemia cell line (Jurkat) and a Burkitt's lymphoma cell line (Raji) were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). The Jurkat and Raji cell lines were used as controls. The cells were all cultured in RPMI‑1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with
10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a humidified incubator in the presence of 5% CO₂. All cell lines were passaged for fewer than six months.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from all cell lines using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). 1 µg Total RNA was reverse transcribed into cDNA using the PrimeScript™ RT Master Mix (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's protocols. RT-qPCR was performed using the SYBR® Premix DimerEraser™ (Takara Biotechnology Co., Ltd.) and an ABI Prism 7500 instrument (Applied Biosystems; Thermo Fisher Scientific, Inc.). The total PCR reaction volume was 20 µl, including SYBR Premix DimerEraser (2X) 10 µl, PCR forward primer (10 µM) 0.6 µl, PCR reverse primer (10 µM) 0.6 µl, ROX Reference Dye II (50X) 0.4 µl, template 2 µl and sterile water 6.4 µl. The PCR cycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 34 sec, and a final extension step of 95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec and 60°C for 15 sec. GAPDH was amplified as an internal control. The specific primer pairs were as follows: ZFAS1, forward, 5'-GCG AAA UCU CTG CTT AAG-3' and reverse, 5'-GGC AGG GAC AAT AGC GTA TG-3'; and GAPDH, forward, 5'-GGACCCTGAC CTGGCTTCTAG-3' and reverse, 5'-TAA GAC GCT GAT GCC CTTGA-3'. Relative mRNA expression was determined using the 2^ΔΔCt method (17). All experiments were independently repeated at least three times.

Transient transfection of small interfering RNA (siRNA). The sequences of ZFAS1 siRNA were as follows: Forward, 5'-UUC AAA AUCCA UCGUAGACC-3' and reverse, 5'-GUACAG AAUGGAUUUGGAG-3'. ZFAS1 siRNA and the negative control siRNA were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). Transfection of siRNA into the AML cell lines HL-60 and SKNO-1 was performed with Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Following 48 h transfection, cells were collected and applied to the subsequent assay.

Cell proliferation assay. Following 24 h transfection with siRNA, 1x10^3 cells/well were seeded in 96-well plates with 100 µl culture medium in triplicate. Cell proliferation was evaluated by water-soluble tetrazolium salt at the indicated time points using a Cell Counting kit-8 (CCK-8, Beyotime Institute of Biotechnology, Haimen, China). Briefly, 10 µl CCK-8 solution was added to each well and the mixture was incubated for 3 h at 37°C, 5% CO₂. Absorbance (450 nm) was determined at 24, 48, 72 and 96 h using a microplate reader (Epoch; BioTek Instruments, Inc., Winooski, VT, USA).

Flow cytometric analysis. For flow cytometric analysis, siRNA transfected HL-60 and SKNO-1 cells were collected following 48 h transfection. HL-60 and SKNO-1 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.). For cell cycle analysis, cells were fixed overnight in 70% cold ethanol, then resuspended in 20 mg/ml propidium iodide (PI; BD Biosciences, Franklin Lakes, NJ, USA). For apoptosis analysis, cells were stained with Annexin V-fluorescein isothiocyanate (FITC) and PI. Cells were then washed twice with ice-cold PBS and put into binding buffer (5 µl Annexin V-FITC and 5 µl PI) for a 30 min incubation. A FACSCalibur™ flow cytometer (BD Biosciences) was used for analyzing the cell cycle or apoptosis. All experiments were independently repeated at least three times.

Statistical analysis. All data are expressed as mean ± standard deviation. Differences between groups were analyzed using an independent-samples t-test. All P-values were two-sided and P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of ZFAS1 in AML cell lines. To determine whether ZFAS1 expression was dysregulated in AML cell lines, levels of ZFAS1 mRNA expression in HL-60, KG-1, ML-1, SKNO-1, Jurkat and Raji cell lines were measured using RT-qPCR. Relative levels of ZFAS1 mRNA were significantly increased in all human four AML cell lines compared with the T lymphocytic leukemia cell line or Burkitt's lymphoma cell line (P<0.001 for HL-60, SKNO-1 and ML-1; P<0.01 for KG-1; Fig. 1A and B).

Efficiency of siRNA in downregulating ZFAS1 expression in AML cells. According to the aforementioned result, two AML cell lines (HL-60 and SKNO-1) were selected for ZFAS1 knockdown by transfection of siRNA, as expression of ZFAS1 was markedly increased in these cell lines compared with the KG-1 and ML-1 cell lines. RT-qPCR demonstrated that ZFAS1 was significantly decreased in HL-60 and SKNO-1 cells transfected with ZFAS1 siRNA compared with the respective negative control (P<0.001; Fig. 1C and D).

Downregulating ZFAS1 expression inhibits AML cell proliferation. The CCK-8 assay determined that the proliferation of HL-60 and SKNO-1 cells were both significantly inhibited following transfection with ZFAS1 siRNA after 72 h (both P<0.05; Fig. 1E) and 96 h (both P<0.01; Fig. 1F). Additionally, flow cytometric analysis of cell cycle distribution indicated that ZFAS1 knockdown significantly increased the percentage of G0/G1 phase HL-60 (from 47-64%; P<0.01; Fig. 2A) and SKNO-1 cells (from 48-63%; P<0.01; Fig. 2B), and decreased the percentage of S-phase HL-60 (from 27-43%; P<0.01; Fig. 2A) and SKNO-1 cells (from 27-40%; P<0.01; Fig. 2B). In summary, these results indicate that ZFAS1 promotes AML cell growth in vitro.

Downregulating ZFAS1 expression promotes AML cell apoptosis. To elucidate the function of ZFAS1 in the regulation of apoptosis in AML cells, flow cytometric analysis of HL-60 and SKNO-1 cell lines was performed. Compared with the respective negative control, ZFAS1 knockdown significantly increased the percentage of apoptotic AML HL-60 (5.5±0.6% vs. 15.7±0.9%; P<0.01; Fig. 3A) and SKNO-1 cells (3.2±0.7% vs. 10.4±0.8%; P<0.05; Fig. 3B). These results suggest that ZFAS1 knockdown promotes AML cell apoptosis, which may contribute to the inhibition of AML progression.
Figure 1. Reverse transcription-quantitative polymerase chain reaction was used to determine the relative mRNA expression of ZFAS1 in four acute myeloid leukemia cell lines (HL-60, SKNO-1, KG-1 and ML-1) compared with (A) T lymphocytic leukemia (Jurkat) and (B) Burkitt's lymphoma (Raji) cell lines. Knockdown effects of siRNA ZFAS1 in (C) HL-60 and (D) SKNO-1 cells. A cell counting kit-8 assay was used to investigate the function of long non-coding RNA ZFAS1. Downregulation of ZFAS1 inhibited (E) HL-60 and (F) SKNO-1 cell growth. Statistics were performed using the independent samples t-test. Data are presented as the mean ± standard deviation. All assays were performed in triplicate. *P<0.05, **P<0.01 and ***P<0.001 vs. control. si, small interfering; NC, negative control; ZFAS1, zinc finger antisense 1.

Figure 2. Flow cytometric analysis was used to determine the role of ZFAS1 on the cell cycle in HL-60 and SKNO-1 cells. Downregulation of ZFAS1 promoted (A) HL-60 and (B) SKNO-1 cell cycle arrest at the G0/G1 phase. Statistical analysis was performed using the independent samples t-test. Data are presented as the mean ± standard deviation. All assays were performed in triplicate. **P<0.01 vs. NC. si, small interfering; NC, negative control; ZFAS1, zinc finger antisense 1.
LncRNAs are a newly identified type of non-coding RNA that have been reported to be dysregulated in a number of different diseases, including carcinoma (18,19). The importance of lncRNAs in the development of cancer may be associated with their ability to influence cellular function through different mechanisms, such as proliferation, apoptosis and differentiation (20-22). In present study, CCK-8 assay and cell cycle distribution analysis demonstrated that ZFAS1 was able to induce AML cell proliferation. Furthermore, the apoptosis assay indicated that ZFAS1 inhibited apoptosis in AML cells. These results suggest that ZFAS1 knockdown suppresses AML HL-60 and SKNO-1 cell proliferation and survival, and that ZFAS1 may act as an oncogenic lncRNA.

It has previously been determined that ZFAS1 is downregulated in breast cancer and that it acts as a putative tumor suppressor (11). Previous studies have reported that ZFAS1 is overexpressed in hepatocellular and colorectal cancer tissues and cell lines (12,13). In the current study, it was demonstrated that ZFAS1 has an oncogenic role in AML cell lines. However, the underlying mechanism of ZFAS1 in the progression of AML remains unclear.

In recent years, a number of articles have reported that lncRNAs have the ability to target and regulate microRNAs (miRs) (23,24). It is widely acknowledged that miRNAs regulate the expression of multiple target genes that encode proteins, which may lead to biological alterations in function (25,26). Li et al (12) identified that ZFAS1 functions as an oncogene in hepatocellular carcinoma progression by binding miR-150 and abrogating its tumor-suppressive function. Furthermore, Li et al (12) indicated that miR-150 was able to repress hepatocellular carcinoma cell invasion by inhibiting ZEB1 and the matrix metalloproteinases (MMPs), MMP14 and MMP16. It was also demonstrated that other lncRNAs are associated with cell growth and apoptosis regulation by regulating multiple target genes, including phosphoinositide-3-kinase, Akt and extracellular signal-regulated kinases (27,28). Although it has been demonstrated that lncRNAs influence epigenetic gene regulation (6,7), proliferation (7), apoptosis (6,7) and prognosis (8) in solid tumors, few studies have identified their effects on AML. Garzon et al (29) assessed whether a lncRNA expression profile was associated with clinical features, molecular abnormalities and outcome in older patients with cytogenetically normal AML and revealed that patients with an unfavorable lncRNA score had a shorter overall survival and disease-free survival rate than those with a favorable lncRNA score. These results are consistent with those from the present study.

In conclusion, the present study demonstrated that lncRNA ZFAS1 promoted the proliferation and suppressed the apoptotic rate of AML cells. Additionally, the results of the present study indicated that ZFAS1 may act as an oncogenic lncRNA.

Acknowledgements

The present study was supported by funding from the Departments of Hematology and Medical Oncology, Third Affiliated Hospital of Wenzhou Medical University, Ruian, China. The funding sources had no role in the study design, in the collection, analysis and interpretation of data, writing of the manuscript or in the decision to submit the manuscript for publication.
